LGLudivine Grzelak

Ludivine Grzelak

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Ludivine Grzelak has a total of 300 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Étude du mode d'action des anticorps dans deux contextes différents : infection par le virus SARS-CoV-2 et traitement par anticorps anti-CD20

    by Ludivine Grzelak

    Les anticorps sont une des composantes essentielles du système immunitaire des vertébrés, et sont produits après infection ou vaccination. Ils possèdent plusieurs activités : une activité de neutralisation (liaison au pathogène qui bloque l'infection) et des fonctions médiées par leur fragment constant Fc. Les anticorps recrutent et activent d'autres effecteurs de l'immunité tels que les cellules Natural Killer (NK), le complément ou les macrophages/monocytes. Ils peuvent induire différents phénomènes antiviraux, tels que la cytotoxicité cellulaire dépendante des anticorps (ADCC), la cytotoxicité dépendante du complément (CDC) et la phagocytose dépendante des anticorps (ADCP). Ces différentes fonctions varient avec chaque anticorps. Nous nous sommes intéressés au mécanisme d'action de deux catégories d'anticorps. Nous avons étudié les anticorps produits après infection par le virus SARS-CoV-2. Nous nous sommes aussi penchés sur les mécanismes de régulation de l'efficacité des anticorps monoclonaux thérapeutiques anti-CD20. Nous avons tout d'abord mis en place un test de détection sensible et spécifique des anticorps anti-SARS-CoV-2 basé sur la cytométrie de flux, qui nous a permis d'identifier des personnes convalescentes de la COVID-19. Nous avons étudié la durée de la réponse humorale et démontré que les niveaux d'anticorps diminuaient au cours du temps et ce d'autant plus rapidement chez les individus masculins. Nous avons comparé les fonctions des anticorps provenant de personnes ayant fait une infection asymptomatique ou symptomatique. Nous avons confirmé que les anticorps produits après infection neutralisaient le virus, et induisaient ADCC et CDC, de façon similaire chez les individus symptomatiques et asymptomatiques. Nous avons aussi étudié l'impact des anticorps présents dans les prélèvements nasopharyngés de patients infectés par le variant Alpha ou des variants précédents. Nous avons démontré que ces anticorps inhibaient le virus dans la plupart des cas, que les résultats des tests antigéniques étaient cohérents avec la présence de virus infectieux et que le variant Alpha était associé à une libération accrue de cytokines. Les anticorps sont produits par le système immunitaire face à un pathogène mais peuvent également être produits en laboratoire pour être utilisés en tant que thérapie. Les anticorps anti-CD20, tels que Rituximab, Ofatumumab et Obinutuzumab, sont largement utilisés pour traiter des pathologies liées aux lymphocytes B, car le CD20 est présent sur ces cellules jusqu'au stade plasmocytaire. L'injection des anti-CD20 provoque une déplétion des lymphocytes B par apoptose et autres fonctions effectrices. Certains patients sont cependant résistants au traitement ou subissent des rechutes. Nous avons étudié les mécanismes régulant l'efficacité de ces anticorps utilisés en clinique. Nous avons réalisé un test de criblage afin d'identifier les protéines cellulaires impliquées dans l'échappement aux anti-CD20. Nous avons démontré que le facteur de transcription IRF8 (Interferon Regulatory Factor 8) est impliqué dans l'expression de CD20 dans les lymphocytes B normaux ou tumoraux, en particulier dans les lymphomes diffus à grandes cellules B. Une diminution des niveaux d'IRF8 est responsable d'une moins bonne efficacité de trois anti-CD20 en culture cellulaire. En conclusion, nous avons démontré que les anticorps anti-SARS-CoV-2 étaient polyfonctionnels. Nous avons également décrit un nouveau mécanisme de régulation des niveaux de CD20 par IRF8 qui impacte l'efficacité des anticorps thérapeutiques anti-CD20.

  • Open Access

    SARS-CoV-2 antibody responses in children exhibit higher FcR engagement and avidity than in adults

    by Carolyn A. Cohen, Ludivine Grzelak, Susan S. Chiu, David Sc Hui, Mike Yw Kwan, Owen Ty Tsang, Wai Hung Chan, Yat Sun Yau, Kelly Wk Lee, Masashi Mori, et al.

    As intrinsic differences in humoral immune response to SARS-CoV-2 between children and adults remain unclear, we improved characterisation by defining the kinetics, specificity and function of antibodies to SARS-CoV-2 in children (n = 146, aged 9.4 ± 4.8 years with n = 257 samples) compared to adults (n = 85, aged 39.5 ± 15.2 years with n = 122 samples). We used plasma samples from an infection and vaccination-naive cohort study with RT-PCR confirmed ancestral B.1* SARS-CoV-2 virus infection with asymptomatic or mild disease, collected in Hong Kong between March to December 2020, from acute (0–14 days post infection) to convalescent (15–206 days) timepoints. Children had significantly lower primary antibody responses against SARS-CoV-2 proteins overall, leading to a less isotype switched response. While children had lower OC43 Spike and SARS-CoV-2 S2 IgG and avidity than adults, they exhibited higher avidities for SARS-CoV-2 whole Spike and Nucleocapsid, and higher levels of Spike FcγR-binding antibodies. Adults’ SARS-CoV-2 antibody responses could be derived from high avidity pre-existing cross-reactive common cold coronavirus B cell responses, whilst children appear to generate a de novo SARS-CoV-2- specific Spike and Nucleocapsid IgG with robust Fc receptor (FcR) binding ability and high avidity at a higher proportion than adults, thus their responses are more targeted and functional for SARS-CoV-2.


  • Open Access

    Resistance of Omicron subvariants BA.2.75.2, BA.4.6 and BQ.1.1 to neutralizing antibodies

    by Delphine Planas, Timothée Bruel, Isabelle Staropoli, Florence Guivel-Benhassine, Françoise Porrot, Piet Maes, Ludivine Grzelak, Matthieu Prot, Said Mougari, Cyril Planchais, et al.

    Convergent evolution of SARS-CoV-2 Omicron BA.2, BA.4 and BA.5 lineages has led to the emergence of several new subvariants, including BA.2.75.2, BA.4.6. and BQ.1.1. The subvariants BA.2.75.2 and BQ.1.1 are expected to become predominant in many countries in November 2022. They carry an additional and often redundant set of mutations in the spike, likely responsible for increased transmissibility and immune evasion. Here, we established a viral amplification procedure to easily isolate Omicron strains. We examined their sensitivity to 6 therapeutic monoclonal antibodies (mAbs) and to 72 sera from Pfizer BNT162b2-vaccinated individuals, with or without BA.1/BA.2 or BA.5 breakthrough infection. Ronapreve (Casirivimab and Imdevimab) and Evusheld (Cilgavimab and Tixagevimab) lost any antiviral efficacy against BA.2.75.2 and BQ.1.1, whereas Xevudy (Sotrovimab) remained weakly active. BQ.1.1 was also resistant to Bebtelovimab. Neutralizing titers in triply vaccinated individuals were low to undetectable against BQ.1.1 and BA.2.75.2, 4 months after boosting. A BA.1/BA.2 breakthrough infection increased these titers, which remained about 18-fold lower against BA.2.75.2 and BQ.1.1, than against BA.1. Reciprocally, a BA.5 breakthrough infection increased more efficiently neutralization against BA.5 and BQ.1.1 than against BA.2.75.2. Thus, the evolution trajectory of novel Omicron subvariants facilitated their spread in immunized populations and raises concerns about the efficacy of most currently available mAbs.


  • IRF8 regulates efficacy of therapeutic anti‐CD20 monoclonal antibodies

    by Ludivine Grzelak, Ferdinand Roesch, Amaury Vaysse, Anne Biton, Rachel Legendre, Françoise Porrot, Pierre‐Henri Commère, Cyril Planchais, Hugo Mouquet, Marco Vignuzzi, et al.

    Anti‐CD20 monoclonal antibodies such as Rituximab, Ofatumumab, and Obinutuzumab are widely used to treat lymphomas and autoimmune diseases. They act by depleting B cells, mainly through Fc‐dependent effectors functions. Some patients develop resistance to treatment but the underlying mechanisms are poorly understood. Here, we performed a genome‐wide CRISPR/Cas9 screen to identify genes regulating the efficacy of anti‐CD20 antibodies. We used as a model the killing of RAJI B cells by Rituximab through complement‐dependent‐cytotoxicity (CDC). As expected, the screen identified MS4A1, encoding CD20, the target of Rituximab. Among other identified genes, the role of Interferon Regulatory Factor 8 (IRF8) was validated in two B‐cell lines. IRF8 KO also decreased the efficacy of antibody‐dependent cellular cytotoxicity and phagocytosis (ADCC and ADCP) induced by anti‐CD20 antibodies. We further show that IRF8 is necessary for efficient CD20 transcription. Levels of IRF8 and CD20 RNA or proteins correlated in normal B cells and in hundreds of malignant B cells. Therefore, IRF8 regulates CD20 expression and controls the depleting capacity of anti‐CD20 antibodies. Our results bring novel insights into the pathways underlying resistance to CD20‐targeting immunotherapies.


  • Open Access

    Poor sensitivity of iPSC-derived neural progenitors and glutamatergic neurons to SARS-CoV-2

    by Marija Zivaljic, Mathieu Hubert, Ludivine Grzelak, Giulia Sansone, Uwe Maskos, Olivier Schwartz

    COVID-19 is a respiratory disease affecting multiple organs including the central nervous system (CNS), with a characteristic loss of smell and taste. Although frequently reported, the neurological symptoms remain enigmatic. There is no consensus on the extent of CNS infection. Here, we derived human induced pluripotent stem cells (hiPSC) into neural progenitor cells (NPCs) and cortical excitatory neurons to study their permissiveness to SARS-CoV-2 infection. Flow cytometry and western blot analysis indicated that NPCs and neurons do not express detectable levels of the SARS-CoV-2 receptor ACE2. We thus generated cells expressing ACE2 by lentiviral transduction to analyze in a controlled manner the properties of SARS-CoV-2 infection relative to ACE2 expression. Sensitivity of parental and ACE2 expressing cells was assessed with GFP- or luciferase-carrying pseudoviruses and with authentic SARS-CoV-2 Wuhan, D614G, Alpha or Delta variants. SARS-CoV-2 replication was assessed by microscopy, RT-qPCR and infectivity assays. Pseudoviruses infected only cells overexpressing ACE2. Neurons and NPCs were unable to efficiently replicate SARS-CoV-2, whereas ACE2 overexpressing neurons were highly sensitive to productive infection. Altogether, our results indicate that primary NPCs and cortical neurons remain poorly permissive to SARS-CoV-2 across the variants’ spectrum, in the absence of ACE2 expression.


  • Open Access

    Potent human broadly SARS-CoV-2–neutralizing IgA and IgG antibodies effective against Omicron BA.1 and BA.2

    by Cyril Planchais, Ignacio Fernández, Timothée Bruel, Guilherme Dias de Melo, Matthieu Prot, Maxime Beretta, Pablo Guardado-Calvo, Jérémy Dufloo, Luis M. Molinos-Albert, Marija Backovic, et al.

    Memory B-cell and antibody responses to the SARS-CoV-2 spike protein contribute to long-term immune protection against severe COVID-19, which can also be prevented by antibody-based interventions. Here, wide SARS-CoV-2 immunoprofiling in Wuhan COVID-19 convalescents combining serological, cellular, and monoclonal antibody explorations revealed humoral immunity coordination. Detailed characterization of a hundred SARS-CoV-2 spike memory B-cell monoclonal antibodies uncovered diversity in their repertoire and antiviral functions. The latter were influenced by the targeted spike region with strong Fc-dependent effectors to the S2 subunit and potent neutralizers to the receptor-binding domain. Amongst those, Cv2.1169 and Cv2.3194 antibodies cross-neutralized SARS-CoV-2 variants of concern, including Omicron BA.1 and BA.2. Cv2.1169, isolated from a mucosa-derived IgA memory B cell demonstrated potency boost as IgA dimers and therapeutic efficacy as IgG antibodies in animal models. Structural data provided mechanistic clues to Cv2.1169 potency and breadth. Thus, potent broadly neutralizing IgA antibodies elicited in mucosal tissues can stem SARS-CoV-2 infection, and Cv2.1169 and Cv2.3194 are prime candidates for COVID-19 prevention and treatment.


  • Open Access

    IRF8 regulates efficacy of therapeutic anti-CD20 monoclonal antibodies

    by Ludivine Grzelak, Ferdinand Roesch, Amaury Vaysse, Anne Biton, Françoise Porrot, Pierre-Henri Commère, Cyril Planchais, Hugo Mouquet, Marco Vignuzzi, Timothée Bruel, et al.

    Anti-CD20 monoclonal antibodies such as Rituximab, Ofatumumab and Obinutuzumab are widely used to treat lymphomas and autoimmune diseases. They act by depleting B cells, mainly through Fc-dependent effectors functions. Some patients develop resistance to treatment but the underlying mechanisms are poorly understood. Here, we performed a genome-wide CRISPR/Cas9 screen to identify genes regulating the efficacy of anti-CD20 antibodies. We used as a model the killing of RAJI B cells by Rituximab through complement-dependent-cytotoxicity (CDC). As expected, the screen identified MS4A1 , encoding CD20, the target of Rituximab. Among other identified genes, the role of Interferon Regulatory Factor 8 (IRF8) was validated in two B-cell lines. IRF8 knockout also decreased the efficacy of antibody-dependent cellular cytotoxicity and phagocytosis (ADCC and ADCP) induced by anti-CD20 antibodies. We further show that IRF8 is necessary for efficient CD20 transcription. Levels of IRF8 and CD20 RNA or proteins correlated in normal B cells and in hundreds of malignant B cells. Therefore, IRF8 regulates CD20 expression and controls the depleting-capacity of anti-CD20 antibodies. Our results bring novel insights into the pathways underlying resistance to CD20-targeting immunotherapies.


  • Open Access

    Type I interferon response and vascular alteration in chilblain‐like lesions during the COVID‐19 outbreak*

    by L. Frumholtz, J.‐D. Bouaziz, M. Battistella, J. Hadjadj, R. Chocron, D. Bengoufa, H. Le Buanec, L. Barnabei, S. Meynier, O. Schwartz, et al.

    SummaryBackground. The outbreak of chilblain‐like lesions (CLL) during the COVID‐19 pandemic has been reported extensively, potentially related to SARS‐CoV‐2 in


  • Open Access

    Analysis of T‐cell responses directed against the spike and/or membrane and/or nucleocapsid proteins in patients with chilblain‐like lesions during the COVID‐19 pandemic

    by C. Cassius, M. Merandet, L. Frumholtz, D. Bergerat, A. Samri, C. Grolleau, L. Grzelak, O. Schwartz, N. Yatim, P. Moghadam, et al.


  • Open Access

    Release of infectious virus and cytokines in nasopharyngeal swabs from individuals infected with non-alpha or alpha SARS-CoV-2 variants: an observational retrospective study

    by Blandine Monel, Delphine Planas, Ludivine Grzelak, Nikaïa Smith, Nicolas Robillard, Isabelle Staropoli, Pedro Goncalves, Françoise Porrot, Florence Guivel-Benhassine, Nathalie Demory Guinet, et al.